Barrington Research analyst Michael Petusky has trimmed his price target for shares of Healthways to $13 from $18 following the population health services company’s quarterly report and the unveiling of a wide-ranging restructuring plan. Petusky still has Healthways at ‘outperform.’
Over at Barclays, Josh Raskin is still a little more guarded at ‘underweight.’ He also has cut his target for Healthways shares (Ticker: HWAY), which closed Tuesday at $11.48, to $12 from $15.
Two longtime Healthways analysts on Friday cut their price targets for the population health management play after new and interim CEO Alfred Lumsdaine said 2015 profits will not meet expectations. But both Brooks O'Neil at Dougherty and Sean Wieland at Piper Jaffray are not telling investors to stop buying the company's shares, keeping Healthways at 'buy' and 'overweight' ratings, respectively. O'Neil's target for Healthways, which on Friday fell 20 percent to $12.40 (Ticker: HWAY), has come all the way down to $15 from $25. Wieland is staying more upbeat: His target now stands at $25.50, down from $27.
The skies are decidedly brighter for shareholders of Acadia Healthcare, which has climbed about 25 percent so far in 2015 after rising by about a third last year. Mizuho Securities analysts see even better days ahead and have launched coverage of the Franklin-based company with an 'outperform' rating at a price target of $84. Acadia (Ticker: ACHC) closed Friday trading at $76.47.
POSTDATA: WARRANTY DEEDS